Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma

Abstract

Cyclophilin B, SART2, SART3, p53, MRP3, AFP, and hTERT were immunogenic targets for HCC immunotherapy. TAA-specific immunotherapy combined with HCC treatments and anti-CTLA-4 antibody has the possibility to produce stronger tumor-specific immune responses.